Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02348008
Title Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Arkadiusz Z. Dudek, MD
Indications

clear cell renal cell carcinoma

Therapies

Bevacizumab + Pembrolizumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.